OLMA News and Press, Olema Pharmaceuticals Inc. From 02/21/23

SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s ...

SAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) today announced that Sean Bohen, M.D., President and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conferen...

OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- breast cancer, with no dose-limiting toxicities, and no observed drug-drug interaction No induced metabolism of palbociclib and no safety interaction was observed Overall tolerability profile o...

SAN FRANCISCO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced two poster presentations on OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective...

Presented preliminary results from OP-1250 Phase 1/2 dose expansion study demonstrating favorable tolerability, high drug exposure, and strong anti-tumor activity at the 34th EORTC-NCI-AACR Symposium Initial clinical data for OP-1250 in combination with CDK 4/6 inhibitor, palb...

SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of t...

The following slide deck was published by Olema Pharmaceuticals, Inc. in conjunction with this event. For further details see: Olema Pharmaceuticals (OLMA) Presents at 34th EORTC-NCI-AACR Symposium

OP-1250 continues to demonstrate favorable tolerability, high drug exposure, and strong anti-tumor activity in preliminary Phase 1/2 study results presented at the 34 th EORTC-NCI-AACR Symposium Initial clinical data for OP-1250 in combination with CDK 4/6 inhibito...

SAN FRANCISCO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the Company will present updated clinical results from the OP-1250-001 study at the 34 th EORTC-NCI-AACR Symposiu...

Olema Pharmaceuticals ( NASDAQ: OLMA ) said it granted stock options to four new employees to buy a total of 58.3K common shares, effective Oct. 3. The awards were granted under Olema's 2022 Inducement Plan, the company said in an Oct. 4 press release. The stock op...